logo
Menu

We provide briefings on technologies to different public stakeholders, from those delivering care and research funders stimulating innovation, to policy makers and advisory bodies. Most, if not all of these briefings, will be publicly available on this website via the search window.

Innovation Observatory > Reports > Drugs > Lisocabtagene Maraleucel (Liso-Cel) for Relapsed/Refractory Diffuse Large B-cell Lymphoma

< Back

Lisocabtagene Maraleucel (Liso-Cel) for Relapsed/Refractory Diffuse Large B-cell Lymphoma

Drugs

Cancer and Palliative Care

February 2018


Non-Hodgkin’s lymphoma (NHL) is a type of cancer of the lymphatic system, and diffuse large B-cell lymphoma (DLBCL) is a common type of NHL. DLBCL develops from abnormal B-cells (a type of white blood cell), with the abnormal cells being larger than normal, healthy B-cells. The abnormal cells in DLBCL are spread diffusely throughout the tumour. The causes of DLBCL are not known, but most people diagnosed with the disease are aged 65 years and over, and the disease affects slightly more men than women.
Lisocabtagene maraleucel (Liso-Cel) is a therapy that uses the patient’s own cells to fight the cancer. Healthy white blood cells are taken from the patient’s blood and re-programmed to fight the cancer cells in DLBCL. When these cells are returned to the body, the programmed cells act by tracking down and destroy the cancer cells. If licensed, this therapy would provide a new kind of treatment for patients whose DLBCL has come back after previous successful treatment (relapsed) or where the disease has not responded to previous treatment (refractory). This therapy also has the potential to improve patient treatment by being available in an outpatient setting when compared to similar treatments that have to be administered in a hospital/specialist setting.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts